Joint Initiative in Vaccine Economics 5

 描述（申请人提供）：作为JIVE第5阶段的一部分，提出的研究项目组合将为各种利益相关者提供关键信息，包括ACIP成员，CDC决策者，患者，提供者和付款人，通过利用各种各样的经济和相关的方法，以回答一系列的研究问题，解决健康的人2020年的目标，有关疫苗接种和疫苗覆盖率。JIVE研究小组将与CDC共同研究人员合作，进行分析，为高优先级疫苗政策决策提供相关经济数据。JIVE研究人员在这种合作方式中拥有丰富的经验，代表了向ACIP和其他利益相关者提供政策相关经济信息的既定流程。这些研究将利用研究调查员团队的广泛专业知识进行创新研究。该研究团队在成本效益分析、疾病建模、疾病特异性专业知识、调查方法专业知识和调查医生的丰富经验方面拥有广泛的专业知识。传染病模拟模型将与健康经济模型相结合，以评估流感和肺炎球菌疫苗接种对糖尿病患者的影响。这将是第一次在糖尿病患者中检查这两种疫苗的经济评估。另一项研究将评估潜在诺如病毒疫苗的健康经济学。这将是第一次使用动态传染病模拟模型来评估潜在诺如病毒疫苗的价值并捕获间接影响的经济分析。联合分析方法将应用于一个新的应用领域，提供者报销，以确定疫苗接种库存和建议的障碍。这些和其他相关方法代表了经济和决策分析方法的新应用，为高度优先的疫苗政策问题提供信息。从拟议的研究中预期的结果包括：·量化接种流感和肺炎球菌疾病的糖尿病个体的价值·通过评估接种这一高危群体的负担来评估预防糖尿病的价值。 ·准备对潜在的诺如病毒疫苗进行经济分析。 ·确定潜在的诺如病毒疫苗具有成本效益的条件。 ·确定哪些报销程序是医生储存和推荐疫苗的最大障碍·检查报销政策的变化如何影响供应商储存和推荐疫苗的决定。这些研究将为高度优先的疫苗政策决策提供相关的经济见解。

 DESCRIPTION (provided by applicant): The portfolio of research projects proposed as part of JIVE, Phase 5, will provide key information for a variety of stakeholders, including ACIP members, CDC decision makers, patients, providers, and payers, by utilizing a wide variety of economic and related methodological approaches in order to answer a series of research questions that address the Healthy People 2020 Objectives relating to vaccination and vaccination coverage. Working jointly with CDC co-investigators, the JIVE research team will conduct analyses to provide relevant economic data for high-priority vaccine policy decisions. This collaborative approach, in which the JIVE research investigators have extensive experience, represents an established process for providing policy-relevant economic information to the ACIP and other stakeholders. These studies will draw on the wide breadth of expertise available in the team of research investigators to create innovative research. The research team has extensive expertise in cost- effectiveness analysis, disease modeling, disease-specific expertise, survey methods expertise, and extensive experience surveying physicians. An infectious disease simulation model will be combined with a health-economic model to evaluate the effects of influenza and pneumococcal vaccination on diabetics. This will be the first economic evaluation to examine both of these vaccines in diabetics. Another study will evaluate the health-economics of a potential norovirus vaccine. This will be the first economic analysis to use a dynamic infectious disease simulation model to evaluate the value of a potential norovirus vaccine and capture indirect effects. Conjoint analysis methods will be applied to a novel application area, provider reimbursement, to identify barriers to vaccination stocking and recommendations. These and other related approaches represent the use of novel applications of economic and decision analysis methods to inform high-priority vaccine policy questions. Anticipated findings from proposed studies include: • Quantifying the value of vaccinating diabetic individuals for influenza and pneumococcal diseases • Assessing of the value of preventing diabetes by evaluating the burden of vaccinating this high-risk group. • Preparing for an economic analysis of a potential norovirus vaccine. • Identifying the condition under which a potential norovirus vaccine would be cost-effective. • Determining what reimbursement procedures are the biggest barriers to physician stocking and recommending vaccines • Examining how changing reimbursement policies might affect provider decisions to stock and recommend vaccines. These studies will provide relevant economic insights into high-priority vaccine policy decisions.